ANTENGENE CORP. DL-0001 (722 F) stock market data APIs

€0.3046 0(0%)
as of July 4, 2025
Try our APIs with free plan!

ANTENGENE CORP. DL-0001 Financial Data Overview

Price chart is built with Anychart

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors. It also develops other clinical stage assets, such as ATG-022, an antibody-drug conjugate which is in Phase II for the treatment of patients with advanced or metastatic gastric cancer; ATG-031, an anti-CD24 monoclonal antibody, which is in Phase I for the treatment of advanced solid tumors; ATG-037, an CD73 inhibitor that is in Phase I for the treatment of locally advanced or metastatic solid tumors; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is I Phase I trial for the treatment of advanced/metastatic solid tumors and B-cell non Hodgkin lymphoma (B-NHL). In addition, the company's pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor; ATG-201 a CD19 x CD3 T cell engager; ATG-102, a LILRB4 x CD3 T cell engager; ATG-106, a CDH6 x CD3 T cell engager; ATG-107, a FLT3 x CD3 T cell engager; and ATG-110, a LY6G6D x CD3 T cell engager. Further, the company develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.

Prev. Close 0.3046
Open 0.3046
High 0.3046
Low 0.3046
52 wk Range 0.025-0.46
Market Cap 198 M
Shares Outstanding 611 M
Revenue 91 950 K
Beta 1.114

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get ANTENGENE CORP. DL-0001 data using free add-ons & libraries


Get ANTENGENE CORP. DL-0001 Fundamental Data

ANTENGENE CORP. DL-0001 Fundamental data includes:

  • Net Revenue: 91 950 K
  • EBITDA: -347 073 984
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get ANTENGENE CORP. DL-0001 Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: NaN
  • EPS/Forecast: NaN
GET THE PACKAGE

Get ANTENGENE CORP. DL-0001 End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE
Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat